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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is predicted to become a major cause of death
worldwide. Studies on the variability in the estimates of key epidemiological parameters of COPD may contribute
to better assessment of the burden of this disease and to helpful guidance for future research and public policies.
In the present study, we examined differences in the main epidemiological characteristics of COPD derived from
studies across countries of the European Union, focusing on prevalence, severity, frequency of exacerbations and
mortality, as well as on differences between the studies’ methods.
Methods: This systematic review was based on a search for the relevant literature in the Science Citation Index
database via the Web of Science and on COPD mortality rates issued from national statistics. Analysis was finally
based on 65 articles and Eurostat COPD mortality data for 21 European countries.
Results: Epidemiological characteristics of COPD varied widely from country to country. For example, prevalence
estimates ranged between 2.1% and 26.1%, depending on the country, the age group and the methods used.
Likewise, COPD mortality rates ranged from 7.2 to 36.1 per 10
5 inhabitants. The methods used to estimate these
epidemiological parameters were highly variable in terms of the definition of COPD, severity scales, methods of
investigation and target populations. Nevertheless, to a large extent, several recent international guidelines or
research initiatives, such as GOLD, BOLD or PLATINO, have boosted a substantial standardization of methodology in
data collection and have resulted in the availability of more comparable epidemiological estimates across countries.
On the basis of such standardization, severity estimates as well as prevalence estimates present much less variation
across countries. The contribution of these recent guidelines and initiatives is outlined, as are the problems
remaining in arriving at more accurate COPD epidemiological estimates across European countries.
Conclusions: The accuracy of COPD epidemiological parameters is important for guiding decision making with
regard to preventive measures, interventions and patient management in various health care systems. Therefore,
the recent initiatives for standardizing data collection should be enhanced to result in COPD epidemiological
estimates of improved quality. Moreover, establishing international guidelines for reporting research on COPD may
also constitute a major contribution.
Background
Chronic obstructive pulmonary disease (COPD) is a pre-
ventable disease characterized by partially irreversible air-
flow limitation due to progressive inflammation of the
lower airways. Smoking is the main risk factor [1,2].
COPD is a common disease whose age-standardized
mortality rate increased during the 1990s, and it is pre-
dicted to be a major cause of death worldwide during the
next two decades [3-5]. With such a high burden on the
healthcare system, emphasis on better diagnosis and man-
agement of the disease must be achieved and reliable epi-
demiological data on the prevalence and severity of COPD
and its exacerbations are crucial to guide decisions.
Indeed, international comparisons of COPD prevalence,
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in this setting.
Differences in healthcare systems and criteria make it
difficult to compare data across different countries [6,7].
Efforts have been made to standardize prevalence esti-
mates through the international Latin American Project
for the Investigation of Obstructive Lung Disease (PLA-
TINO) and Burden of Obstructive Lung Disease
(BOLD) study initiatives, for example [8,9]. To obtain a
representative picture of the epidemiological situation in
Europe and what has been achieved so far, we reviewed
the literature on COPD in Europe, focusing on preva-
lence, severity, exacerbations and mortality. The goal of
the study was to examine the differences in these epide-
miological estimates across countries in light of the dif-
ferences in methods used from one study to another.
Therefore, we collected the following features associated
with the epidemiological estimates reported: publication
date, type of population, sample size and definitions
used (for example, severity scale used, exacerbation defi-
nition used). This review strongly suggests that estab-
lishing reporting guidelines dedicated to COPD studies
may constitute a major contribution to enhancing the
value of COPD research and management by facilitating
comparisons between studies.
Methods
Document search
We sought documents on the prevalence, mortality,
severity and exacerbations of COPD in the Science Cita-
tion Index database via the Web of Science (WOS)
(Thomson Reuters, New York, NY, USA). The search
was limited to documents published between 1991 and
2009, focusing on the epidemiology of COPD (preva-
lence, severity, exacerbations and mortality) in different
populations (general population, patients followed up by
a general practitioner and/or chest specialist, ambulatory
patients and inpatients). We also extracted data from the
European statistical database (Eurostat) [10].
WOS was queried using a four-step strategy as
follows:
1. TS = COPD or chronic obstructive pulmonary
disease or chronic bronchitis
2. TS = Prevalence or severity or mortality or
exacerbation
3. TI = Cancer
4. (2 AND 1) NOT 3
where TI is a term search limited to the title of the
document and TS is a term search in the title, abstract
and keywords.
Document triage and selection
We applied the following exclusion criteria to the WOS
documents obtained using the above strategy: We
excluded documents concerning non-European Union
countries, documents that were not original articles or
reviews and documents with WOS subject categories
not relevant to this study (for example, biophysics, bio-
chemistry, microbiology, psychology, social issues, bioin-
formatics, toxicology). Finally, document eligibility was
completed by deeper examination of the remaining arti-
cles. Articles not dealing primarily with the epidemiol-
o g yo fC O P D( t h a ti s ,p r e v a l e n c e ,s e v e r i t y ,m o r t a l i t y ,
exacerbations) or not specifying sufficiently important
definitions related to the epidemiological estimates (for
example, diagnostic tests used and target population,
including inclusion and exclusion criteria) were
excluded from the review. A comparable search in the
MEDLINE database via the PubMed interface did not
retrieve any additional documents.
The Eurostat database was used to extract age-stan-
dardized COPD mortality rates (deaths per 100,000
inhabitants) for 2007 by using code J40-47 (death as a
result of lower respiratory tract disease) and by exclud-
ing codes J45 and J46 (death as a result of asthma).
Death as a result of bronchiectasis (J47) was not
excluded, because the corresponding number of cases
was considered minor.
Analysis of the collected information
Considering each of the reported epidemiological esti-
mates (prevalence, severity, exacerbations and mortality),
we collected several associated features: publication date,
type of population under study, sample size and defini-
tions used (for example, severity scale used, exacerbation
definition used). We then listed each estimate report
with its associated feature described above to obtain a
picture of the variability of estimates across countries in
light of the methodological differences between studies.
Results
Information included in the review
The process for including final information used in the
review is detailed in Figure 1. The initial literature search
resulted in 7,302 WOS documents, and after applying the
exclusion criteria and eligibility steps, 65 articles (61 in
English, 3 in Spanish [11-13] and 1 in French [14]) were
finally included in the study (Figure 1). COPD mortality
data in the Eurostat database were available for 21 coun-
tries of the European Union.
Prevalence
COPD prevalence data can be categorized into four
types according to the criteria used to define the dis-
ease (Table 1; see also a graph of these data in Addi-
tional file 1, Figure A1), namely, symptoms [15-17],
physician reports [18-23], spirometry [8,11-13,24-39]
and models [40-42].
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Page 2 of 16Surveys based on symptoms (cough and expectoration
on most days for as much as three months per year and
for at least two successive years) were used to estimate
the prevalence of chronic bronchitis (initial stage of
COPD). This prevalence ranged from 2.6% to 9.5% in
adults under 44 years of age [15-17]. Major variability
was noted across European countries, with prevalence
rates ranging from 0.7% to 9.7% (median, 2.6%) in a
study covering 16 countries [17]. There were also signif-
icant regional differences within a given country [17].
The prevalence of chronic bronchitis is reported to be
significantly lower among women than among men in
all countries (2.8% versus 3.7%; P < 0.001) [17]. The pre-
valence increased gradually from nonsmokers to “mod-
erate-heavy” smokers (≥15 packs-yrs) and from higher
socioeconomic classes to the unemployed and blue-col-
lar workers [15-17].
Studies [18-23] based on diagnoses of chronic bronchi-
tis by healthcare professionals have produced less varying
results, with prevalence rates ranging from 3.7% to 5.6%
among adults. In studies based on respiratory function,
such as the ratio of the maximum expiratory volume in 1
second (FEV1) over forced vital capacity [8,11-13,24-39]
or the difference between measured and predicted FEV1
[37], the prevalence ranged from 2.1% [37] to 26.1%
[8,19], but this large range may be attributed in part to
the different types of population in which the prevalence
was estimated. However, differences in population char-
acteristics only partly explain the variability of the
reported prevalence estimates. Even if one limits the
Articles identified through search in the Science 
Citation Index database (Web of Science)(n=7302) 
Chronic Obstructive 
Pulmonary Disease 
mortality data from the 
Eurostat database 
65 original articles + COPD mortality data from 21 countries 
 included in the review 
Excluded articles (n=5147): 
•  Non European Union countries (n=3997)  
•  Neither original article nor review (n=601) 
•  Subject category ≠ medical (microbiology, 
biophysics, psychology, social issue ...) (n=549) 
2155 Documents assessed for eligibility: 
Exclusion of non relevant articles by examining 
title and abstract (n=2090) 
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Figure 1 Flowchart of the process for collecting information included in the review.
Atsou et al. BMC Medicine 2011, 9:7
http://www.biomedcentral.com/1741-7015/9/7
Page 3 of 16Table 1 COPD prevalence data
a
Criteria used to define COPD Country (sample size) Study population Age
b (yr) Prevalence (%)
Symptoms
c
Cerveri et al., 2003 [15] Italy (18,645) General population 20-44 9.5
Huchon et al., 2002 [16] France (14,076) General population ≥25 4.1
Cerveri et al., 2001 [17] 16 countries (14,819) General population 20-44 2.6
Physician reports
Cazzola et al., 2009 [18] Italy (15,229) General population NS 2.5
Schirnhofer et al., 2007 [19] Austria (1,258) General population ≥40 5.6
Montnemery et al., 2006 [20] Sweden (3,692) General population 20-59 3.6
Hedman et al., 1999 [21] Finland (3,102) General population 18-65 3.7
Montnemery et al., 1998 [22] Sweden (8,469) General population 20-59 4.6
Lundback et al., 1991 [23] Sweden (6,610) General population 35-66 4.1
Functional respiratory tests
Miravitlles et al., 2009 [24] Spain (4,274) General population 56.6 (10.7) 10.2
Van Durme et al., 2009 [25] Netherlands (7,983) General population ≥55 11.6
Hansen et al., 2008 [26] Denmark (4,757) General population 45-84 12.0
Bednarek et al., 2008 [27] Poland (1,960) Primary care 56.7 (11.6) 9.3
Roche et al., 2008 [28] France (4,764) Health prevention center 59.9 (10.1) 2.6
Buist et al., 2007 [8] Austria (1,258) General population ≥40 26.1
d
Germany (683) 13.3
Poland (526) 22.1
Norway (638) 18.8
Shahab et al., 2006 [29] United Kingdom (8,215) General population 55.5 (13.5) 13.3
Stavem et al., 2006 [30] Norway (1,619) Occupational cohort 49.8 (5.5) 16.4
Sichletidis et al., 2005 [31] Greece (6,112) General population 21-80 5.6
Murtagh et al., 2005 [32] Ireland (2,484) General population 53.3 (8.6) 6.3
Tzanakis et al., 2004 [33] Greece (888) General population ≥35 8.4
Hasselgren et al., 2001 [34] Sweden (4,814) General population 43 (14.8) 2.1
Peña et al., 2000 [35] Spain (3,978) General population 40-69 9.1
Viegi et al., 2000 [36] Italy (1,727) General population ≥25 11.0 or 18.3
Jaen et al., 1999 [11] Spain (497) General population 20-70 7.2
Dickinson et al., 1999 [37] United Kingdom (353) General population 68.25 9.9
Marco Jordán et al., 1998 [12] Spain (460) General population 40-60 6.8
Renwick & Connolly, 1996 [38] United Kingdom (783) General practitioner 66.1 9.0
Brotons et al., 1994 [13] Spain (642) General population 35-65 6.4
Bakke et al., 1991 [39] Norway (1,275) General population 42 (16.1) 4.5
Models
Peabody et al., 2005 [40] Spain Total population ≥30 6.2
Norway 6.3
Poland 6.7
Feenstra et al., 2001 [41] Netherlands Total population ≥20 1.5
Stang et al., 2000 [42] Spain Total population ≥45 10.3
Italy 11.1
France 10.4
United Kingdom 15.0
aPrevalence estimates are based on symptoms (cough and sputum at least 3 months each year), physician reports, functional respiratory tests (FEV1/FVC ratio
<70%, FEV1 <80% of predicted, FEV1/FVC ratio <65%, FEV1/FVC ratio <70% or FEV1/FVC ratio <88% (male)/89% (female)) and models (general population).
bAge
was reported in various ways distinguished here as follows: “≥ x”, minimum age; “x” or “x (y)”, mean age or mean age (SD); “x-y”, age range i.e. min-max.
cThese
patients had chronic bronchitis.
dThese data are also reported in Schirnhofer et al., 2007 [19]. Abbreviations used: COPD, chronic obstructive pulmonary disease;
NS, not specified; FEV1, maximum expiratory volume in 1 second; FVC, forced vital capacity.
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Page 4 of 16analysis to patients over 40 years of age, the prevalence of
the COPD still varies widely, from 4.5% in Norway [39]
to 26.1% in Austria [8]. The functional criteria used to
diagnose COPD also vary from one study to another,
depending on the classification used: American Thoracic
Society (ATS) [43], British Thoracic Society (BTS) [44],
European Respiratory Society Task Force (ERS) [45], or
Global Initiative for Chronic Obstructive Lung Diseases
(GOLD) [46]. In the international BOLD study [8], based
on the general population and on the current GOLD
guidelines, the prevalence estimates issued from the 12
countries under study significantly varied from one site
to another, with differences between men and women
likely to reflect gender smoking rates. Considering the
sites from the five European countries participating in
the BOLD study, prevalence estimates ranged from 13.3%
in Germany to 26.1% in Austria. In all, six of the nine
papers that used the definition of COPD proposed by
the GOLD initiative refer to the general population
[8,19,24-26,29], and with respect to these data, the preva-
lence estimates range between 10.2% in Spain [24] and
26.1% in Austria [8].
Several authors have proposed model-based approaches
for estimating COPD prevalence [40-42]. These models
combine demographic data with smoking rates [40-42],
data on respiratory function in the general population
[40,42] and other risk factors such as air pollution and low
socioeconomic status [40]. In these studies, the prevalence
varied from 1.5% to 15% in the general population, and a
given model [42] applied to the population over 45 years
of age in four European countries resulted in estimates
varying from 10.3% in Spain to 15% in the United
Kingdom.
Severity
The reported epidemiology of COPD severity [8,14,27,
29,33,36,47-57] depends on whether the analysis con-
cerns the general population [8,29,33,36,47-50], patient
follow-up by a general practitioner and/or chest specia-
list [14,27,51-54] or inpatients (Table 2; see also a graph
of these data in Additional file 2, Figure A2) [55-57].
Moreover, results were also reported according to var-
ious severity scales (Figure 2).
In general patient populations, early-stage disease predo-
minates among people over 40 years of age, with rates
of GOLD 2006 stage 1 disease (FEV1 ≥80% of predicted)
and stage 2 disease (80% < FEV1 ≤ 50% of predicted),
respectively, ranging from 50.7% and 40.7% in Poland to
59.4% and 35.2% in Austria [8]. In a study based on the
GOLD 2003 severity scale and on a younger population
(ages 20 to 44 years), estimates substantially varied from
one country to another: from 51.7% in Switzerland to
89.8% in Spain for stage 0 and from 3.4% in Italy to
16.8% in Denmark for stages 2 and 3. The authors had
no clear explanation for these differences [48]. The pro-
portion of advanced stages increases with age, peaking
at age 60 years. Thus, in a Swedish study based on the
BTS classification [49], the percentage of stage 4 disease,
which was negligible below age 40 years, reached 22.4%
at age 58 or 59 years before decreasing again to 7.3% at
73 or 74 years of age. This increase with age is observed
in both men and women [8]. The relationship between
tobacco consumption and GOLD stage 2 disease or
higher was less clear, partly owing to interference by age
[8]. Moderate forms of the disease are more frequent in
cohorts of patients followed by general practitioners or
specialists, with observed frequencies ranging from 27%
to 56.4% [14,27,51-54].
Analyses of severity among COPD inpatients show,
quite logically, more frequent advanced forms of the dis-
ease, with a dramatic decrease in the proportion of
patients with mild COPD (reported proportions ranging
from 0% to 7.9%). The existence of several severity
scales leads to major variations in the reported epide-
miology of COPD severity, even when considering a
given type of population. Depending on whether the
ERS, ATS, BTS or GOLD criteria are used (Table 2),
the percentage of early stages in the general population
is, respectively, 80%, 98%, 65% and 55%, while advanced
stages represent, respectively, 95%, 67%, 85% and 58% of
cases among COPD inpatients [36,47,56].
In general, there is a relatively low variability in the
severity estimates based on GOLD criteria and derived
from a given type of population. For example, when con-
sidering the general population of patients who are at
least 40 years old, the severity distributions of patients in
Norway [8], Germany [8] and Sweden [47] are similar. In
t h es a m ew a y ,t h es e v e r i t yd i s t r i b u t i o n si np a t i e n t s
recruited from general practitioners and/or specialists in
Sweden [52] and Poland [27] are comparable.
Exacerbations
Tables 3 and 4 list the 22 reports mentioning the fre-
quency of COPD exacerbations in European patients
according to severity stage [53,55,58-77]. The definition
of exacerbation substantially varied from one study to
another (Table 3). The mean number of exacerbations
per person and per year ranges from 0.6 to 3.5 [63,72]
according to the disease stage and the age group (Table
4). Borg et al.’s model [77], in which parametric values
were derived from the literature, used mean frequencies
of exacerbations of, respectively, 0.05 and 1.47 per person
per year at GOLD stages 1 and 4. According to Soler-
Cataluña et al. [55], 26% of very severely affected patients
have at least three exacerbations per year compared to
0% of mildly affected patients. The number of exacerba-
tions can be reduced by treatment [60,66]. Exacerbations
are usually categorized as mild (symptoms treated at
Atsou et al. BMC Medicine 2011, 9:7
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Page 5 of 16Table 2 Severity of COPD
a
Severity
c (%)
Study population Country (sample size) Criteria Age
b (yr) Stage 1 Stage 2 Stage 3 Stage 4
General population
Buist et al., 2007 [8] Austria (1,349) GOLD 2006 ≥40 59.4 35.2 5.4
Germany (713) 55.3 38.6 6.1
Poland (603) 50.7 40.7 8.6
Norway (707) 55.8 37.8 6.4
Shahab et al., 2006 [29] United Kingdom (8,215) GOLD 2006 55.5 (13.5) 41.6 43.9 14.5
Lindberg et al., 2006 [47] Sweden (1,237) GOLD 2006 46-77 57.0 37.0 5.0 1.0
BTS 1997 65.0 27.0 8.0 NA
De Marco et al., 2004 [48]
d Belgium (1,122) GOLD 2003 20-44 58.6 41.4 ND
Denmark (394) 56.4 43.6 ND
France (2,137) 66.7 33.3 ND
Germany (1,983) 64.8 35.2 ND
Italy (910) 69.4 30.6 ND
Ireland (454) 75.3 24.7 ND
Netherlands (1,362) 74.3 25.7 ND
Norway (969) 40.7 59.3 ND
Spain (1,942) 59.2 40.8 ND
Sweden (1,859) 79.3 20.7 ND
Switzerland (853) 76.3 23.7 ND
United Kingdom (1,198) 69.8 30.2 ND
Tzanakis et al., 2004 [33] Greece (888) ERS 1995 ≥35 58.2 25.6 16.2 NA
Jansson et al., 2002 [49] Sweden (212) BTS
e 28-29 75.0 25.0 0 0
43-44 46.6 46.6 6.8 0
49-50 16.0 64.0 12.0 8.0
58-59 15.4 57.7 15.4 11.5
64-65 6.9 29.3 41.4 22.4
73-74 14.3 21.4 47.6 16.7
79-80 9.8 34.2 48.8 7.3
Viegi et al., 2000 [36] Italy (1,727) ERS 1995 ≥25 81.0 14.0 5.0 NA
ATS 1995 98.2 1.8 0 NA
Clinical
f 86.1 13.9
Von Hertzen et al., 2000 [50]
g Finland (7,217) ≥30 59.8 34.1 6.1 NA
General practitioner and/or chest specialist
Izquierdo et al., 2009 [51] Spain (3,619) GOLD 2006 67.0 (10.8) 20.1 54.0 22.1 3.8
Bednarek et al., 2008 [27] Poland (1,960) GOLD 2006 56.7 (11.6) 30.6 51.4 15.3 2.7
Hoogendoorn et al., 2006 [52] Sweden (481) GOLD 2006 65.5 30.0 51.0 17.0 2.0
Piperno et al., 2005 [14] France (3,411) SPLF 1996 58.4 (9.9) 31.3 50.2 18.5 NA
Detournay et al., 2004 [53] France (255) SPLF 1996 67.1 56.0 27.0 17.0 NA
Soriano et al., 2000 [54] United Kingdom (23,277) Prescriptions 66.7 (15.5) 35.5 56.4 8.1 NA
Hospital
Soler-Cataluña et al., 2005 [55] Netherlands (304) GOLD 2006 71 (9) 6.6 35.8 33.6 24.0
Tsoumakidou et al., 2004 [56] Greece (67) ERS 1995 69.0 0 4.5 95.5 NA
BTS 1997 69.5 1.5 14.9 83.6 NA
ATS 1995 67.6 4.5 28.3 67.2 NA
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pital or affecting daily activity) or severe (specialist treat-
ment or inability to work). More severe disease stages are
associated with more severe exacerbations [60,66]. In
Borg et al.’s model [77], the average frequencies of severe
exacerbations are 0.01 and 0.33 per patient per year at
GOLD stage 1 and GOLD stage 4, respectively. Such
estimates have been confirmed by another observational
study [55].
Mortality
As shown in Table 5 (see also a graph of these data in
Additional file 3, Figure A3), reported estimates of
COPD mortality in the general population vary from
Table 2 Severity of COPD
a (Continued)
GOLD 2001 69.5 0 58.2 41.8
Kornmann et al., 2003 [57] Germany (1,434) GOLD 2001 {55} 7.9 73.0 19.1
aCOPD severity data are reported for the general population, inpatients, general practitioner reports, general practitioner and chest specialist reports or are taken
from medical databases.
bAge was reported in various ways distinguished here as follows: “≥ x”, minimum age; “x” or “x (y)”, mean age or mean age (SD); “x-y”,
age range i.e. min-max; “{x}”, median age. mean age (±SD); median age; age range, min-max.
cERS 1995, ATS 1995, BTS 1995 and SPLF 1995 classifications define
only three stages.
dIn this study, based on the GOLD 2003 severity scale, the estimates for stage 0 defining patients at risk of COPD ranged from 51.7% in
Switzerland to 89.8% in Spain.
ePatients with both FEV1/FVC <70% and FEV1 ≥80% (considered as having COPD in the GOLD 2006 classification but not in the
BTS 1995 classification) were also included in the study.
fAirway obstruction of any degree was defined by FEV1/FVC ratio <70% and the severity of obstruction
was graded according to the FEV1 value: mild (FEV1 ≥70% of predicted) and moderate to severe (FEV1 <70% of predicted).
gAirway obstruction of any degree
was defined by FEV1/FVC ratio <80% and the severity of obstruction was graded according to the FEV1/FVC value: 70-79%, minimal to mild; 50-69%, moderate;
<50%, severe. Abbreviations used: COPD, chronic obstructive pulmonary disease; ERS 1995, European Respiratory Society 1995 classification; ATS 1995, American
Thoracic Society 1995 classification; BTS 1995, British Thoracic Society 1995 classification; SPLF 1995, Société de Pneumonologie de Langue Française 1995
classification; GOLD 2001, GOLD 2003 and GOLD 2006, Global Obstructive Lung Disease 2001, 2003 and 2006 classifications; ND, not defined; NA, not applicable;
FEV1, maximum expiratory volume in 1 second; FVC, forced vital capacity.
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Figure 2 The most popular chronic obstructive pulmonary disease classifications: ERS, European Respiratory Society; ATS, American
Thoracic Society; SPLF, Société de Pneumologie de Langue Française; BTS, British Thoracic Society; GOLD, Global Initiative for Chronic
Obstructive Lung Disease; FEV1, forced expiratory volume in 1 second. ATS, BTS, ERS and SPLF classifications define three stages of severity
between 0% and 100% (ATS and ERS) or 80% (BTS and SPLF) of predicted FEV1. The most recent classification is the GOLD classification, which
was initially proposed in 2001 and has been modified twice, in 2003 and 2006. In 2003, the GOLD classification evolved from three to four
stages plus a supplementary stage 0 defining patients at risk (that is, the presence of chronic cough and sputum, but no obstruction together
with FEV1 over forced vital capacity ratio >70%; stage 0 is not shown in the figure), and stage 0 was not kept in the GOLD classification system
in 2006.
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Page 7 of 16one country to another, but data interpretation must be
done carefully. First, the International Classification of
Diseases (ICD) has evolved with time, and the underly-
ing classification or codes used for estimating mortality
(for example, Hurd et al.[78] included codes 495 and
496 corresponding to asthma) are never similar from
one study to another. Overall, mortality estimates have
increased with time. However, increases in COPD mor-
tality and features related to coding of mortality may
both be involved in this increase, with relative parts
Table 3 Exacerbation definitions
a
Diagnostic method Description of symptoms
Treatment
Burge et al., 2003 [58]
b Chest problem requiring treatment with oral corticosteroids and/or antibiotics as defined by the treating
physician
Calverley et al., 2003 [59] Worsening of COPD symptoms that required treatment with antibiotics, oral corticosteroids or both
Jones et al., 2003 [60]
b Chest problems requiring treatment with antibiotics and/or oral corticosteroids
Andersson et al., 2002 [61] Increased dose of current treatment and/or treatment with antibiotics or systemic corticosteroids and/or general
practitioner or outpatient visit or hospital admission
Burge et al., 2000 [62]
b Worsening of respiratory symptoms that required treatment with oral corticosteroids, antibiotics or both as
judged by the general practitioner
Symptoms
Effing et al., 2009 [63] Presence for at least 2 consecutive days of an increase in any two major symptoms or an increase in one major
and one minor symptom
Worth et al., 2009 [64] A complex of at least two respiratory adverse events with a duration of more than 3 days
Schermer et al., 2009 [65] Episode with one or more subsequent unscheduled contacts with either a general practitioner or a chest
physician because of worsening of respiratory symptoms
O’Reilly et al., 2006 [66]
c Symptom-based: Symptom score of at least 2 for 2 consecutive days with no score for at least two of these
symptoms in the previous 5 days Healthcare-based: Need to take antibiotics and/or oral corticosteroids for chest
problem
Wilkinson et al., 2006 [67] Not defined but specified as symptom-based
Donaldson et al., 2003 [68] An increase in either two or more major symptoms or any one major symptom plus any minor symptoms
occurring on 2 or more consecutive days
Seemungal et al., 2000 [69] Presence for at least 2 consecutive days of an increase in any two major symptoms or an increase in one major
and one minor symptom
Treatment and symptoms
Seemungal et al., 2008 [70] Sustained worsening of baseline respiratory symptoms for at least 2 days that required treatment with oral
corticosteroids and/or antibiotics
Tashkin et al., 2008 [71] Increase or new onset of more than one respiratory symptom (cough, sputum, sputum purulence, wheezing or
dyspnea) lasting 3 days or more and requiring treatment with an antibiotic or a systemic corticosteroid
Calverley et al., 2008 [72] Clinically significant worsening of COPD symptoms requiring treatment with antibiotics and/or systemic steroids
Wedzicha et al., 2008 [73] Symptom worsening that required treatment with oral corticosteroids and/or antibiotics or required
hospitalization
Dusser et al., 2006 [74] Onset of at least one clinical descriptor (worsening of dyspnea, cough or sputum production, appearance of
purulent sputum, fever (>38°C), appearance of a new chest radiograph abnormality) lasting ≥2 days and requiring
a new prescription or an increase in the dose of b2-agonists, antibiotics, corticosteroids or bronchodilators
Soler-Cataluña et al.,
2005 [55]
Sustained increase in respiratory symptomatology compared with baseline requiring modification of regular
medication and hospital treatment (acute exacerbation of COPD)
Oostenbrink et al., 2004 [75] Complex of respiratory symptoms (new onset or worsening of more than one symptom such as cough, sputum,
dyspnea or wheeze) lasting for ≥3 days
Brusasco et al., 2003 [76] Complex of respiratory symptoms (new onset or an increase in at least one of the following: cough, sputum,
dyspnea, wheeze, chest discomfort) lasting at least 3 days and usually associated with therapeutic intervention
Model
Borg et al., 2004 [77] Increase in any two major symptoms (dyspnea, sputum purulence, sputum amount) or an increase in one major
and one minor symptom (wheeze, sore throat, cough, and symptoms of a common cold, which were nasal
congestion and/or discharge) for at least 2 consecutive days
Not defined
Detournay et al., 2004 [53] ND
aCriteria used to define exacerbations were symptoms, treatment, symptoms and treatment or model-based. COPD stages are defined according to GOLD
[53,55,59-62,66-69,74-77,90], BTS [61] and SPLF [53] criteria.
bThese three articles concern the same patients (the Inhaled Steroids in Obstructive Lung Disease
trial).
cHealthcare-based definition of exacerbation corresponds to the “treatment and symptoms"-based definition. Abbreviations used: COPD, chronic obstructive
pulmonary disease; BTS, British Thoracic Society classification; GOLD, Global Obstructive Lung Disease classification; SPLF, Société de Pneumonologie de Langue
Française classification.
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Page 8 of 16Table 4 COPD exacerbations
a
Exacerbation definition group
(study type
b)
Country (sample size) Classification
(stage of COPD)
Mean number of
exacerbations per patient
and per year
c
Treatment
Treatment
Burge et al., 2003 [58]
d (CT) United Kingdom (524) GOLD (2 or 3) 1.6-1.7 Placebo
1.1-1.4 Fluticasone propionate
Calverley et al., 2003 [59] (CT) 25 countries (1,974) GOLD (2 or 3) 1.3 Placebo
1.0 Salmeterol
1.0 Fluticasone
1.0 Salmeterol and fluticasone
Jones et al., 2003 [60]
d (CT) United Kingdom (751) GOLD (1 or 2) 1.0 Placebo
0.7 Fluticasone
GOLD (3 or 4) 1.7 Placebo
1.5 Fluticasone
Andersson et al., 2002 [61] (CT) Sweden (191) GOLD/BTS 1.2
Burge et al., 2000 [62]
d (CT) United Kingdom (751) GOLD (2 or 3) 1.9 (2.6) Placebo
1.4 (1.9) Fluticasone
Symptoms
Effing et al., 2009 [63] (CT) Netherlands (142) GOLD (2 or 3) 3.5 (2.7)
Worth et al., 2009 [64]
e (CT) Germany (220) GOLD (3 or 4) 0.9 Placebo
0.4 Cineole
Schermer et al., 2009 [65] (CT) Netherlands (286) GOLD (1-3) 0.7 Placebo
0.9 Fluticasone
1.0 N-acetylcysteine
O’Reilly et al., 2006 [66] (OS) United Kingdom (309) GOLD (1 or 2) 2.2 [1.9-2.7] Symptom-defined
2.3 [2.0-2.8] Healthcare-defined
GOLD (3 or 4) 2.5 [2.1-2.9] Symptom-defined
3.2 [2.8-3.7] Healthcare-defined
Wilkinson et al., 2006 [67] (OS) United Kingdom (74) GOLD (2 or 3) 2.5 {1.3-3.8}
Donaldson et al., 2003 [68] (OS) United Kingdom (132) GOLD (2 or 4) 2.5 {1.3-3.9}
Seemungal et al., 2000 [69] (OS) United Kingdom (101) GOLD (2 or 4) 2.4 {1.3-3.8}
Treatment and symptoms
Seemungal et al., 2008 [70] (CT) United Kingdom (109) GOLD (2 or 3) 2.0 Placebo
1.0 Erythromycin
Tashkin et al., 2008 [71] (CT) 37 countries (5,993) GOLD (2-4) 0.8 Placebo
0.7 Tiotropium
Calverley et al., 2008 [72] (CT) 11 countries (911) GOLD (2 or 3) 1.0 Placebo
0.6 Mometasone furoate
Wedzicha et al., 2008 [73] (CT) 20 countries (1,323) GOLD (3 or 4) 1.3 SFC
1.3 Tiotropium
Dusser et al., 2006 [74] (CT) France (1,010) GOLD (1 or 2) 2.0 Placebo
1.2 Tiotropium
GOLD (3 or 4) 1.8 Placebo
2.7 Tiotropium
Soler-Cataluña et al., 2005 [55] (OS) Spain (304) GOLD (1) (75, 25, 00)
f
GOLD (2) (60, 35, 05)
f
GOLD (3) (56, 32, 12)
f
GOLD (4) (34, 40, 26)
f
Oostenbrink et al., 2004 [75] (CT) Netherlands and Belgium (519) GOLD (1-4) 1.0 (0.1) Placebo
0.7 (0.1) Fluticasone
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a (Continued)
Brusasco et al., 2003 [76] (CT) 18 countries (1,207) GOLD (2 or 3) 1.5 Placebo
1.2 Salmeterol
1.1 Tiotropium
Model
Borg et al., 2004 [77] (M) Netherlands GOLD (1) (0.05, 0.07, 0.01)
g
GOLD (2) (1.01, 1.31, 0.14)
g
GOLD (3) (1.06, 1.45, 0.17)
g
GOLD (4) (1.47, 1.72, 0.33)
g
Not defined
Detournay et al., 2004 [53] (OS) France (255) Moderate 1.7
Moderate to 1.5
severe
Severe 2.0
aCriteria used to define exacerbations were symptoms, treatment, symptoms and treatment or model-based. COPD stages are defined according to GOLD
[53,55,59-62,66-69,74-77,90], BTS [61] and SPLF [53] criteria.
bStudy type reported as CT, clinical trial; OS, observational study; M, model.
cMean numbers of
exacerbations per person and per year were reported in various ways: mean exacerbation or mean exacerbation (±SD) or mean exacerbation {min-max} or [95%
confidence interval].
dThese three articles concern the same patients (the Inhaled Steroids in Obstructive Lung Disease trial).
eThese estimates are based on 6
months of follow-up. The mean exacerbation in both groups during the previous year was 3.2.
fThis article does not give the mean number of exacerbations but
the proportion of patients who had, respectively, no acute exacerbations, one, two or three or more.
gMean number of exacerbations per person and per year
reported separately for mild, moderate and severe exacerbations. Abbreviations used: COPD, chronic obstructive pulmonary disease; BTS, British Thoracic Society
classification; GOLD, Global Obstructive Lung Disease classification; SPLF, Société de Pneumonologie de Langue Française classification; SFC, salmeterol and
fluticasone propionate (anti-inflammatory drug combination); ISOLDE, the Inhaled Steroids in Obstructive Lung Disease trial.
Table 5 COPD age-standardized mortality rates
a
Annual mortality rate
(per 100,000 inhabitants)
Population Country Year(s) Age (yr) Global Male Female Classification codes used
General population
Eurostat
b,c [10] Austria 2007 19.4 30.8 12.1 ICD 10 (J40-J44, J47)
Bulgaria 15.8 26.7 07.9
Cyprus 09.3 15.5 04.7
Czech Republic 14.7 24.1 08.5
Estonia 10.7 24.2 04.4
Finland 12.9 25.3 05.4
France 07.2 12.5 03.8
Germany 16.3 24.9 10.8
Greece
d 10.9 14.8 07.9
Hungary 36.1 56.5 23.6
Lithuania 22.4 49.0 08.5
Latvia 09.7 22.4 03.0
Malta 16.0 35.4 02.7
Netherlands 26.0 39.6 18.7
Poland 16.8 32.0 07.8
Romania 20.6 33.8 11.4
Spain 18.4 37.1 06.1
Sweden 15.1 17.6 13.6
Slovakia 12.8 24.5 05.9
Slovenia 13.2 23.4 07.5
United Kingdom 28.4 35.5 23.7
Hurd et al., 2000 [78] Austria 1997 35-74 32 6 ICD 9 (490-496)
Bulgaria 1994 38 8
France 1995 26 5
Germany 1997 28 11
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Page 10 of 16hardly quantifiable. At present, the fairest comparison
between countries should be made with 2007 European
COPD-related mortality estimates issued by Eurostat
[10]. The estimates ranged from 7.2 per 100,000 inhabi-
tants in France to 36.1 per 100,000 inhabitants in Hun-
gary, and mortality was between 1.3 (Sweden) and 13
(Malta) times higher in men than in women. Mortality
estimates among hospital inpatients are high, as
expected, at around 25% [79,80] or even higher in
patients with comorbidities [81]. The mortality of hospi-
talized patients with COPD increases with the number
of exacerbations: In the study by Soler-Cataluña et al.
[55], patients with 0, 1 or 2 and 3 or more acute COPD
exacerbations per year had 36-month survival probabil-
ities of 0.86, 0.70 and 0.42, respectively.
Discussion
This study describes the variability of reported COPD
epidemiological data in European countries. Although
the search of documents was limited to the WOS and
Eurostat databases, the collected information was suffi-
cient to outline how international standardization of
research methodology has evolved over time and has
contributed to estimates of better quality. In that regard,
whereas documents not included in the present study,
such as unpublished information, might be available
through national health surveys or other initiatives, their
additional value to this study is likely to be low.
As shown, one of the main reasons for the variability
of the reported epidemiological estimates is the use of
different methods by different authors, hindering valid
Table 5 COPD age-standardized mortality rates
a (Continued)
Greece 1996 12 1
Hungary 1995 75 23
Italy 1993 30 4
Netherlands 1995 43 15
Poland 1996 43 8
Portugal 1996 38 7
Romania 1996 61 18
Spain 1995 45 6
Sweden 1996 22 12
United Kingdom 1997 48 31
Siafakas et al., 1995 [45] Austria 1988-1991 NS 18 6 ICD 9 (490-493)
Belgium 28 9
Bulgaria 11 6
Denmark 34 20
Finland 22 4
France 10 3
Greece 03 2
Hungary 40 16
Italy 25 8
Netherlands 20 5
Poland 29 8
Portugal 14 5
Romania 20 12
Spain 10 3
Sweden 11 5
United Kingdom 12 6
Hospital population
e
Gudmundsson et al., 2006
f [81] SweNorFin
g 2002 72.1 ± 8.7 293 ICD 10 (J40-J47)
Groeneweger et al., 2003
h [79] Netherlands 2001 70.6 ± 8.5 230 COPD-ATS
Almagro et al., 2002
i [80] Spain 1999 72.0 ± 9 220 COPD
j
aAge was reported in various ways: mean age (±SD), or age range, min-max.
bNot all European countries have COPD mortality data for 2007 in the Eurostat
database.
cTotal population (all ages).
dGreece does not have mortality data for asthma in 2007; these estimates correspond to J40-J47 and not to J40-J44, J47.
eMortality rates in inpatients are of course not age-standardized but represent the number of deaths per 100,000 inhabitants.
fMortality rates at 1 year for stages
GOLD 1 and GOLD 2, GOLD 3, and GOLD 4 are 3.6, 6.9, and 13.7, respectively.
gThis study concerned Sweden, Norway and Finland.
hMortality rate at 6 months
was 18.
iMortality rates at 6 and 24 months were, respectively, 13.4 and 35.6.
jClinical diagnosis of COPD and forced spirometry at discharge showing FEV1 <70%
of the reference value and FEV1/FVC ratio <70%. Abbreviations used: ICD, International Classification of Diseases. COPD-ATS, chronic obstructive pulmonary
disease as defined by the American Thoracic Society; NS, not specified; GOLD, Global Obstructive Lung Disease classification stage; FEV1, maximum expiratory
volume in 1 second; FVC, forced vital capacity.
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Page 11 of 16comparisons. For example, prevalence estimates were
based on a wide variety of methods (for example, symp-
toms, physician reports, spirometry, models), different
populations (for example, general population, hospital
inpatients), different age distributions and different defi-
nitions of COPD. Studies based on a small number of
patients and on interviews (symptoms or physician
reports) are not as reliable as larger studies based on
spirometry. Methods basedo ns y m p t o m sa r en e i t h e r
specific nor sensitive for the diagnosis of COPD. The
use of a screening questionnaire (and questionnaires
m a ya l s ov a r yf r o mo n es t u d yt oa n o t h e r )d o e sn o t
allow thorough investigation of the specific characteris-
tics of the patients, and the lack of functional investiga-
tions means that questions on progression from cough
and sputum production to airflow obstruction remain
unanswered [15]. The same applies to studies based on
physician reports. Thus, inas t u d yo fag i v e ng e n e r a l
population sample, the estimated prevalence is, respec-
tively, 5.6% and 26.1%, depending on whether one uses
physician reports or spirometry [19]. The use of differ-
ent severity scales is another important source of het-
erogeneity [19]. For example, among 212 patients
included in the Obstructive Lung Disease in Northern
Sweden surveys, 179 had COPD in the BTS classifica-
tion, whereas all had COPD on the basis of the GOLD
2006 criteria, including patients with FEV1 ≥80% of the
predicted level (mild form) [49]. Because of these meth-
odological problems and imprecise definitions, the terms
chronic bronchitis and chronic obstructive pulmonary
disease often were not differentiated in the past. How-
ever, these methodological limitations do not entirely
explain the observed epidemiological variability. Other
factors such as smoking and age probably contribute to
the observed variability. A recent study considering
COPD patients randomly selected from registers in a
Swedish region indicated that only 59% had an initial
diagnosis that involved spirometry [82], and in fact only
longitudinal studies of young populations could allow
early diagnosis and refine our knowledge of the natural
history of COPD. In the recent largest international
study on COPD, the BOLD study, prevalence data based
on spirometry according to GOLD guidelines were col-
lected at 12 sites in different countries, 5 of which were
located in Europe [8]. Interestingly, these prevalence
estimates are within the same range as those reported in
the PLATINO study of five Latin American countries
[9]. These results likely reflect the benefits of the inter-
national standardization of methodology. Nevertheless,
the BOLD study reported significant differences across
the different sites (P < 0.0001), but the authors under-
lined the danger of extrapolating data from such sites
(a pool of about 150,000 people) to national populations.
Therefore, the present national prevalence estimates that
may be twice those from one European country to
another (Table 1) should still be considered with
caution.
As observed with regard to prevalence, a large epide-
miological variability is observed with respect to COPD
severity, but our study indicates that severity is the para-
meter for which recent standardization has resulted in
the best improvement of estimates. Besides, severity is a
very active research domain. In recent years, several
composite scores, such as the BODE index (body mass
index, airflow obstruction, dyspnea and exercise capa-
city), ADO index (age, dyspnea and airflow obstruction)
or the DOSE index (dyspnea, airflow obstruction, smok-
ing status and exacerbation frequency) [83,84], have
been proposed for grading patients’ disease severity. At
present, the GOLD severity scale is the international
standard, and our results indicate that recent estimates
from the international studies based on this classifica-
tion generally represent relatively low differences in the
distribution of severity from one country to another
within a given type of population.
This situation contrasts with the reported data on
exacerbations for which the GOLD initiative did not
recommend methodological guidelines. Unsurprisingly,
exacerbation data clearly indicate that severe COPD is
associated with more frequent and more severe exacer-
bations, but estimates of the frequency of exacerbations
depend largely on the definition used [59,66,76]. Exacer-
bations are variously defined as a complex of respiratory
symptoms or as a complex of respiratory symptoms
requiring steroid or antibiotic treatment (Table 4). The
influence of age and smoking status on exacerbations is
poorly documented. The main COPD management
objective is currently to prevent exacerbations. Most
estimates concerning exacerbations come from thera-
peutic trials, which focus on selected populations and in
which the frequency of exacerbations is used to judge
treatment efficacy. As underlined by Aaron et al.[85],
standardizing counts, analyses and method of reporting
exacerbations are of major importance for a fair evalua-
tion of treatments tested in randomized controlled trials.
Although several studies have reported COPD mortal-
ity data [45,78-81], the mortality data in the general
population issued by Eurostat are those allowing the
most standardized comparison between countries. The
ICD is an international standard for categorizing mortal-
ity data, but the reliability of mortality estimates is under-
mined by problems of coding [86]. In addition, since
some researchers think that there is a considerable over-
lap between asthma and COPD in adults, some COPD
mortality estimates may be overestimated. Conversely,
COPD mortality is also underreported [87], and causes of
death remain to be standardized among patients with
several comorbidities [16]. It may be difficult to get a
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Page 12 of 16great deal of consistency, because patients with COPD
often do not die as a result of acute exacerbations of
COPD or respiratory failure. More often they die as a
result of cardiovascular causes, cancer, pneumonia and
other related conditions. It can be challenging and diffi-
cult to decide which ICD code to use in recording the
death certificate. More work is needed to come up with a
realistic method of assessing the mortality rate in COPD.
Finally, observed variations in COPD mortality rates
across countries include variations in performance of the
local healthcare systems with respect to COPD patient
management, but indicators permitting such compari-
sons in specific settings are lacking.
The difficulties in comparing COPD studies outlined in
this review can be attributed to two distinct reasons.
First, the methodological bases may vary from one study
to another, such as the definition of COPD. Nevertheless,
our study also shows that efforts to establish congruence
among COPD definitions and study methods are under-
way. Second, regardless of the methodology used for
performing the study, the method of reporting results,
such as exacerbation data, may vary from one report to
another. This may also concern the reporting of impor-
tant features related to the disease, such as smoking his-
tory. Smoking consumption (patients may be categorized
in arbitrary classes of pack-year consumption) was used
in some studies, whereas others used a three smoking
status categorization (never smoker, former smoker, cur-
rent smoker). There are current guidelines for reporting
research, but they are based on the methodological type
of the studies [88]. Our study strongly suggests that
establishing reporting guidelines dedicated to COPD stu-
dies may constitute a major contribution to enhancing
the value of COPD research and management by facilitat-
ing comparisons between studies.
Conclusions
COPD is a major public health problem [89]. The wide
range of prevalence, severity and mortality estimates
across European countries cannot possibly correspond
to real differences, but it remains difficult to assess the
part of this heterogeneity due to methodological issues
and the part of this heterogeneity due to countries’
characteristics, such as differences in national smoking
exposure. National prevalence estimates are still far
from perfect, impairing fair comparisons from one
country to another. The present study outlines that with
time, congruence of COPD definitions, especially in
terms of severity classification, and methodological stan-
dardization have resulted in more comparable epidemio-
logical estimates, but much remains to be made in
terms of exacerbation data. Many international efforts
have been made to develop common rules for coding
mortality data, but they concern all diseases, and
potential improvements of COPD mortality data are
likely to poorly depend on specific COPD programs.
Efforts to establish common standardized COPD defini-
tions and study methods are underway, and researchers
are encouraged to do more to better assess the disease
and the relative effectiveness of methods of patient man-
agement in different European Union member states. In
that regard, the establishment of international guidelines
for reporting research on COPD may constitute an
important contribution. Indeed, the present review
strongly supports the use of commonly agreed guide-
lines for bringing more uniformity to the findings
reported in future studies. Our results emphasize the
need for scientists and investigators to work harder at
adopting common guidelines that may be imperfect but
nevertheless acceptable, so that the epidemiological
database can be richer, the burden of the disease can be
better defined and the response of patients with COPD
to treatment can be better evaluated.
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